The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis

• Published in: BMJ open 2019-08, Vol.9 (8), p.e031531-e031531
• Main Authors: Naheed, Salma, Holden, Chloe, Tanno, Lulu, Jaynes, Eleanor, Cave, Judith, Ottensmeier, Christian H, Pelosi, Giuseppe
• Format: Article
• Language: English
• Subjects: Biomarkers; Breast cancer; carcinoid; Cell cycle; Classification; Evidence-based medicine; Ki-67; Medical prognosis; Meta-analysis; Metastasis; neuroendocrine; Neuroendocrine tumors; Oncology; Prostate; Proteins; Systematic review
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2019-031531

IntroductionThe omission of the immunohistochemical proliferation marker Ki-67 labelling index (henceforth, simply Ki-67) from the 2015 WHO classification system of pulmonary neuroendocrine tumours (Lung-NETs) as a prognostic and grading criterion remains controversial. This systematic review along with meta-analysis will be conducted to assess the prognostic/grading utility of Ki-67 in Lung-NETs.MethodsThis systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A systematic search of MEDLINE Ovid, Embase, Scopus and the Cochrane Library will be performed from the inception of each database to 28 February 2019 for studies investigating any role of Ki-67 in Lung-NETs. Only full papers published in English detailing survival outcomes and HRs according to Ki-67 will be included. The primary endpoint will be establishing whether Ki-67 is a reliable marker in determining prognosis and thus assessing grade of Lung-NETs patients.Ethics and disseminationEthical approval will not be required as this is an academic review of published literature. Findings will be disseminated through the preparation of a manuscript for publication in a peer-reviewed journal as well as presentation at national and international conferences.PROSPERO registration numberCRD42018093389